ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities (8-page issue).

May 23, 2003

Conte Institute Leafs Scientific Effort On Central Europe Environmental Clean-Up

March 19, 1993

FDA’s Commitment To Cancer No Different Than Other Diseases, Kessler Tells Advocate

August 14, 1992

DOD Bill Passes Senate; Prostate Cancer Gets $75 Mil.; Breast Cancer Recieves $175 Mil.

June 25, 1999

Breast Cancer Family History Doesn’t Increase Risk Of Ovarian Cancer, Study Says

September 30, 2005

BRM Phase 1-2 Task Orders Awarded

November 21, 1980